Introduction {#s1}
============

Self-poisoning with pesticides is a major public health problem in many developing countries, accounting for up to one-third of all suicides worldwide according to recent estimates \[[@pmed-0050049-b001]\]. While organophosphorus insecticides are by far the leading cause of morbidity and mortality in these self-poisonings, other pesticides are important in specific regions and countries \[[@pmed-0050049-b002],[@pmed-0050049-b003]\]. Paraquat (1,1′-dimethyl-4,4′-bipyridinium dichloride) is a nonselective contact herbicide that has been widely used in many countries since the 1960s. Following ingestion of large amounts of concentrated formulation, the rapid development of multi-organ failure and cardiogenic shock is almost universally fatal. When smaller amounts are ingested, paraquat is actively taken up into pulmonary epithelial cells where redox cycling and free radical generation trigger a fibrotic process that may lead to death \[[@pmed-0050049-b004]--[@pmed-0050049-b007]\].

Survival after acute paraquat poisoning is related to the ingested amount, the circumstances of poisoning, and the formulation ingested \[[@pmed-0050049-b008]\]. While intentional ingestion of paraquat concentrate accounts for most recorded fatalities, the problem of unintentional ingestion prompted the introduction of formulation changes (a blue colour, a stenching agent, and an emetic) to the liquid concentrate in the late 1970s and early 1980s \[[@pmed-0050049-b009]\]. This change is believed to have made a major contribution to the decrease of unintentional paraquat ingestion in many countries \[[@pmed-0050049-b009],[@pmed-0050049-b010]\]. However, mortality following intentional ingestion remains high, and a beneficial effect of these early formulation changes on the survival rate has not been demonstrated \[[@pmed-0050049-b011]\].

GRAMOXONE INTEON is a novel paraquat formulation specifically developed to decrease toxicity through a reduction in the amount of paraquat absorbed from the gastrointestinal tract following ingestion \[[@pmed-0050049-b012]\]. A natural alginate that immediately gels when entering the low-pH environment of the stomach has been incorporated into the formulation and the amount of emetic has been increased. These changes are designed to improve efficacy of emesis after gelling of the formulation in the stomach. An osmotic purgative, magnesium sulphate, has also been added to the INTEON formulation to help speed up the passage of remaining paraquat through the small intestine, the main site of paraquat uptake, thereby reducing overall absorption.

We carried out an observational study to compare the 3-mo survival of patients admitted to hospital following paraquat ingestion before and after the introduction of the new INTEON formulation in Sri Lanka.

Methods {#s2}
=======

Patients {#s2a}
--------

The study was conducted in nine large hospitals (in Galle, Hambantota, Anuradhapura, Polonnaruwa, Colombo, Gampaha, Ratnapura, Kandy, and Peradeniya), covering the main agricultural areas in Sri Lanka, with the exception of the northern and eastern regions. The protocol ([Text S1](#pmed-0050049-sd001){ref-type="supplementary-material"}) was approved by four separate Ethical Committees ([Text S2](#pmed-0050049-sd002){ref-type="supplementary-material"}--[S5](#pmed-0050049-sd005){ref-type="supplementary-material"}) in Sri Lanka with responsibility for surveys/studies conducted in the nine hospitals. Patients were recruited by study physicians into the survey if they reported that they had ingested products containing paraquat or, if the pesticide ingested was unknown, the patient had clinical signs typical of paraquat poisoning (mouth lesions and/or blue colouration around the mouth). Oral informed consent to participate in the survey was sought from patients or their relatives in their native language.

Procedures {#s2b}
----------

Data on the exposure, treatment, and outcome of patients ingesting paraquat were collected prospectively from December 2003 to January 2006. Following review and approval of the registration package by the Office of the Registrar of Pesticides, the new INTEON formulation was introduced in October 2004 and stocks of the existing formulation were actively withdrawn from distributors and retailers. The pesticide, bottle, and label were similar to the standard formulation, the only differences being that the INTEON formulation was slightly more viscous, and the batch numbers differed. INTEON also included a tracer compound (500 ppm diquat) that could be detected in blood and urine following oral ingestions.

Data were collected by trained research assistants using a standardised questionnaire. Upon admission, demographic data (age, sex, and weight) were recorded together with information relating to previous treatments and transfer from a primary hospital. Details relating to the ingestion were taken: time of exposure; circumstances (intentional self-harm, accidental, homicide, or occupational); time to emesis; and number and force of vomiting episodes. The patient was asked to state the ingested volume from a range of quantities (\<5 ml to \>150 ml) with a variety of measuring schemes (millilitres, fluid ounces, or various-sized spoon/cup measures).

A plasma and/or urine sample was taken soon after admission, where possible. Samples were stored frozen and sent to Syngenta CTL (Alderley Park, Macclesfield, Cheshire, UK) for determination of paraquat ion concentration and detection of the tracer compound diquat ion to classify the case as either standard formulation or INTEON. Analysis was conducted using HPLC, LC-MS-MS, and LC fluorescence \[[@pmed-0050049-b013]\].

Details of treatments and clinical observations throughout the patients\' stay in hospital and clinical outcome were recorded; if the patient was discharged from hospital, study doctors visited the patient at home at least 3 mo after the initial exposure to ascertain survival.

Cases were initially recorded on paper and then transferred to a Microsoft Access database. For quality control, a separate database was created from data collected from the medical notes by an auditor (this was not possible in two of the hospitals where permission for access to the medical records archives was refused). The two databases were compared to assess completeness of case ascertainment and to highlight differences in recording of details.

To find out whether the pattern of patient admissions to, and referrals from, hospitals not participating in the survey had changed over time, the study team contacted 147 hospitals and care units towards the end of the survey in the provinces where the study hospitals were located. Using a structured questionnaire, information was obtained from physicians who were in charge of admitting patients, or, in the case of central dispensaries, from the pharmacists.

Case Definition and Power Calculation {#s2c}
-------------------------------------

Both standard and INTEON formulation cases were classified as 'confirmed\' on the basis of blood or urine analysis and as 'probable\' when bottle or label were presented ([Table 1](#pmed-0050049-t001){ref-type="table"}). The recording of the first two consecutive confirmed INTEON cases at each hospital was taken to indicate that INTEON use had become common in the area, and a washout period was defined for each hospital from 1 October 2004 until that time point. Cases after the washout period without sample confirmation or evidence from the bottle/label were classified as 'possible\' INTEON cases.

###### 

Categorisation of Cases into Standard Formulation and INTEON Formulation Groups

![](pmed.0050049.t001)

The power calculation was based on the Mantel-Haenszel risk ratio estimate stratified for three ingestion groups and indicated that a total of 210 cases would give \> 85% power to detect a 2-fold reduction in potency for a two-sided test with significance level of 5%. It was decided to use the number of confirmed INTEON cases to close the survey in order to achieve adequate power for the sensitivity analyses. The number of confirmed cases fell below 210 after some patients were identified with admission records at more than one hospital after transferring between hospitals and other patients had to be excluded because they did not meet the study entrance criteria. However, the total number of INTEON cases (confirmed, probable, and possible) included in the analyses exceeded 210.

Statistical Analysis {#s2d}
--------------------

Means and proportions for baseline variables were compared between the two ingestion groups using Student\'s *t* test for continuous variables and the *χ* ^2^ test for categorical variables. The primary analysis compared survival among standard formulation cases before 1 October 2004 with survival among confirmed, probable, and possible INTEON formulation cases after the washout period. In sensitivity analyses, survival among all confirmed and probable standard formulation cases was compared with survival among all confirmed and probable INTEON formulation cases.

Time to death analyses were performed using both nonparametric analysis methods (Kaplan--Meier survival curve estimates and the Mantel--Cox log rank test) and semiparametric methods (Cox proportional hazards \[PH\] regression models). Standard errors for 3-mo survival estimates were obtained using Greenwood\'s method \[[@pmed-0050049-b014]\]. All statistical analyses were performed using Stata version 9.

Cox PH regression models were used to estimate unadjusted and adjusted hazard ratios for the INTEON formulation. Adjusted analyses always included terms for the following covariates: (a) sex, age, and weight of participant; (b) treatments received; (c) use of adsorbent; and (d) time from ingestion to presentation at a medical centre.

Estimated ingestion amount was an important factor influencing survival, but information was not available for a number of cases. Consequently, unadjusted and adjusted hazard ratios were also derived for the subset of patients who had ingestion information. Adjustment was performed with and without estimated ingestion amount in the regression model. Ingestion amount was included as a categorical variable (eight levels) but also as a continuous variable using the logarithms of the midpoint of ingestion categories. Models were also fitted to examine whether the relationship with ingestion amount differed between the two groups. Estimates of relative potency were derived using the slope of the relationship with the logarithm of ingestion amount and term for formulation group in the Cox PH model.

Variation in survival characteristics between the nine study hospitals was investigated using a gamma frailty model (proportional hazard functions with random scaling factors). In addition, evidence of nonproportional hazard functions was assessed by visual methods and by testing the significance of the interaction with the logarithm of survival time. Stratification was used to account for nonproportionality of the hazard functions.

Results {#s3}
=======

Information was collected by the nine study hospitals on 774 patients over the study period. The numbers of participants eligible for the primary analysis and sensitivity analyses broken down by formulation are given in [Table 2](#pmed-0050049-t002){ref-type="table"}. The primary study population included 297 confirmed cases of standard formulation ingestion admitted before 1 October 2004 and 289 confirmed, probable and possible cases of INTEON ingestion. For sensitivity analyses all confirmed or probable cases were used (382 standard formulation and 206 INTEON cases).

###### 

Survey Participants

![](pmed.0050049.t002)

The two primary study populations were similar for demographic and ingestion variables at baseline ([Table 3](#pmed-0050049-t003){ref-type="table"}). Most patients had ingested paraquat deliberately (93.7% of all cases). Information on ingestion volume was not available for a higher percentage of standard formulation than INTEON cases, and the distribution of cases among the ingestion subgroups was different between the two formulations.

###### 

Demographic and Ingestion Details of Patients in the Formulation Groups

![](pmed.0050049.t003)

The clinical characteristics of the two groups were generally similar ([Table 4](#pmed-0050049-t004){ref-type="table"}), but a significantly higher proportion of INTEON patients vomited within 15 min of ingestion. Just over half of all patients were treated at a primary hospital before being referred to a study hospital and this proportion was higher for patients who had ingested INTEON formulation (57.8% versus 45.5%). Lavage, intravenous fluids, and prednisolone were the only treatments for which there was a significant difference between the two groups. Fewer INTEON patients received these treatments than patients who had ingested the standard formulation paraquat.

###### 

Clinical Details of Patients in the Formulation Groups

![](pmed.0050049.t004)

Follow-up of patients was generally good ([Table 5](#pmed-0050049-t005){ref-type="table"}), but it was not possible to find out whether ten patients (4.4% of those followed up) were still alive at 3 mo. Four INTEON patients were followed up slightly early (a minimum of 11 wk after ingestion) and are described as alive in [Table 5](#pmed-0050049-t005){ref-type="table"}. The proportion of known survivors increased from 76 of 297 patients with the standard formulation to 103 of 289 patients with INTEON ingestion, and there was an increase in estimated 3-mo survival (Kaplan--Meier estimates) among the INTEON patients from 27.1% to 36.7% (difference 9.6%; 95% CI 2.0%--17.1%). Kaplan--Meier survival analysis ([Figure 1](#pmed-0050049-g001){ref-type="fig"}) and log rank test indicated a significant difference between the two survival curves (*p* = 0.002). Median survival time increased from 2.3 d (95% CI 1.2--3.4 d) with the standard formulation to 6.9 d (95% CI 3.3--10.7 d) with INTEON ingestion (*p* = 0.002, log rank test).

###### 

Vital Status of Patients at Three Months Following Paraquat Ingestion in the Formulation Groups

![](pmed.0050049.t005)

![Kaplan-Meier Survival Curves for Patients Ingesting Standard and INTEON Formulation](pmed.0050049.g001){#pmed-0050049-g001}

The overall improvement in survival among patients who had ingested the INTEON formulation was seen in every ingestion group except the \<5 ml group, in which survival was already high. [Figure 2](#pmed-0050049-g002){ref-type="fig"} shows summary Kaplan--Meier survival curves for patients categorised into four ingestion groups (\<10 ml, 10--30 ml, 30--100 ml, and ≥100 ml) for each formulation. In addition, survival curves are shown for patients for whom ingestion information was not available.

![Kaplan-Meier Survival Curves by Formulation Group and Ingestion Amount](pmed.0050049.g002){#pmed-0050049-g002}

Survival following ingestion of INTEON was significantly better than the standard formulation (hazard ratio \[HR\] 0.73, 95% CI 0.60--0.89; *p* = 0.002) in an unadjusted analysis ([Table 6](#pmed-0050049-t006){ref-type="table"}). There was evidence of nonproportionality of the hazard functions of different hospitals, and stratification was used to account for this. However, HR changed only slightly when stratification was made for treatment centre and when covariates other than estimated ingestion amount were included in the model. [Table 6](#pmed-0050049-t006){ref-type="table"} also shows that HRs were smaller when these analyses were restricted to the group of patients with ingestion information, but the fully adjusted analysis (including ingestion amount) for this latter group of patients gave an HR of 0.67 (95% CI 0.52--0.87), which is similar to that seen in the unadjusted analysis for all participants.

###### 

Hazard Ratios for INTEON Formulation from Cox Proportional Hazards Regression Models

![](pmed.0050049.t006)

Replacing the eight-level categorical variable for ingestion amount with the logarithm of the midpoint of ingestion in each category made little difference to the fit of the model (change in *χ* ^2^ = 3.62, 6 df) and there was no evidence of a different relationship with ingestion amount for the standard and INTEON formulations. The HR for a doubling of ingestion amount was 1.57 (95% CI 1.46--1.69). The strong relationship with the logarithm of ingestion amount enables an estimate to be made of the potency (toxicity) of the INTEON formulation relative to the standard formulation. Based on the subset of patients with ingestion information, the potency of INTEON was estimated to be 0.54 of the standard formulation.

Sensitivity analyses including all confirmed and probable cases gave results that were very similar to those obtained in the primary analysis. There was an increase in estimated 3-mo survival among the INTEON patients from 27.4% to 37.9% (difference 10.5%; 95% CI 2.5%--18.6%) and an HR of 0.64 (95% CI 0.50--0.82) with a potency estimate for INTEON of 0.47 of the standard formulation.

Among patients who died there was an increase in median time to death from 0.9 d (interquartile range \[IQR\] 0.5--3.4) for the standard formulation to 1.5 d for INTEON (IQR 0.5--5.5); *p* = 0.02. This effect was more pronounced in the sensitivity analysis, restricted to confirmed and probable cases, where the median time to death was 1.1 d (IQR 0.5--3.9) for the standard formulation but 2.5 d for INTEON (IQR 0.8--9.0); *p* = 0.001.

Monthly admissions of patients with paraquat poisoning to study hospitals showed some seasonal variability, related to the use pattern of paraquat in Sri Lanka ([Figure 3](#pmed-0050049-g003){ref-type="fig"}). However, they also suggest an overall decrease of the number of cases over time. In the separate admission and referral survey of 147 contacted hospitals and care units, 83 (56%) reported having received a total of 541 patients with paraquat poisoning. Nearly two-thirds (63%) of hospitals and care units reported no change in the number of patients seen since the introduction of INTEON, whereas 29% reported a decrease and 8% an increase. Virtually all hospitals that were able to provide information had not changed their referral pattern of paraquat-poisoned patients, and there was no difference between the larger and smaller units.

![Monthly Admission Rates of Patients with Paraquat Poisoning to Study Hospitals According to Outcome at Three Months](pmed.0050049.g003){#pmed-0050049-g003}

Discussion {#s4}
==========

In Sri Lanka, pesticides are the most common means of self poisoning, with case fatality ratios more than 10-fold higher than those from self-poisoning in industrialised countries \[[@pmed-0050049-b015]\]. Although not the most common cause of pesticide death, paraquat has a higher case fatality ratio than other commonly ingested pesticides \[[@pmed-0050049-b016]\]. We have shown in this study that the development of a new formulation that turns to a gel in the stomach, slowing absorption and increasing the time available for effective emesis, increases estimated 3-mo survival from 27.1% for patients ingesting the standard formulation to 36.7% with the INTEON product. In individual terms this equates to approximately 30 lives saved within the survey due to the introduction of INTEON.

Despite much research into the mechanism of toxicity and the potential for treatment of paraquat poisoning, no specific therapy has so far been shown to affect outcome in controlled clinical studies \[[@pmed-0050049-b005],[@pmed-0050049-b006],[@pmed-0050049-b017]\]. Consequently, prevention of absorption remains an important approach to reduce paraquat toxicity. For this reason a potent emetic has been included in paraquat formulations since the late 1970s \[[@pmed-0050049-b009]\]. However, a beneficial effect of this measure on case fatality has not been conclusively demonstrated \[[@pmed-0050049-b011],[@pmed-0050049-b018]--[@pmed-0050049-b022]\]. This may be related to the relatively large quantities of product that are often ingested in self-harm cases.

Paraquat causes mucosal damage and increases passive flux across the mucosal barrier at high concentrations \[[@pmed-0050049-b023]\], and peak plasma levels occur within one hour, since the liquid formulation rapidly reaches the absorptive site in the small intestine \[[@pmed-0050049-b006]\]. The principle of the INTEON formulation is based on the addition of alginates, which become protonated after contact with gastric acid and transformed into a gelatinous mixture. This technology is used in pharmaceuticals to treat heartburn and acid reflux \[[@pmed-0050049-b024]\] and to cause satiety in the treatment of obesity, by virtue of the intragastric bulking of alginates \[[@pmed-0050049-b025]\]. In vitro and in vivo studies have shown that the inclusion of the alginate into the formulation led to a decrease in paraquat absorption \[[@pmed-0050049-b012]\]. The combination of the alginate with an increased emetic concentration and magnesium sulphate added as purgative is considered to be necessary to achieve an optimum safening effect. The INTEON formulation introduced into Sri Lanka also contained a built-in surfactant system. Some of the formulation ingredients were found to gradually separate out in the bottle with prolonged storage, creating a surfactant and emetic-rich phase, and one with increased paraquat and alginate concentration. Although the formulation could be easily rehomogenised by light agitation of the bottle the overall safening effect may potentially have been suboptimal.

Although steps were taken to actively withdraw the old product from the market when the new formulation was introduced, we recognised that there would be a period in which the old product would still be with farmers. It was therefore important to unequivocally identify as many cases as possible through analysis of the marker that had been added to the INTEON product in a plasma or urine sample. However, this identification was possible only in two-thirds of the INTEON cases due to a combination of samples not being taken (e.g., in patients who were very ill on admission and died quickly) and samples with plasma paraquat concentrations so low that the diquat marker could not be detected. To reduce the number of standard formulation cases incorrectly included in the INTEON group we introduced washout periods for the centres. During the washout periods only 6/44 (14%) of patients with sample confirmation were INTEON ingestions. In contrast, 195/242 (81%) of patients with samples after the washout period had ingested INTEON. Hence, it is likely that the majority of the 89 possible INTEON cases after the washout period were correctly classified as INTEON cases. Only 18 cases with no sample information or equivocal results occurred during the washout period and had to be excluded from the survival analyses. Importantly, the sensitivity analyses excluding those patients without sample or bottle confirmation gave very similar results to the primary analysis, providing further evidence that our overall classification of cases was largely correct. The possible inclusion of a small number of standard formulation cases in the INTEON group may have had a small impact on the survival rate. However, the effect of not including possible INTEON formulation cases would have been far greater because of (a) missing cases with large ingestion volumes because of the difficulty of collecting samples from very sick patients, and (b) missing ingestions too small for the marker to be detectable in samples.

Ingestion information was not available for 26% of standard formulation cases and 14% of INTEON ingestions. The higher proportion of standard formulation cases with missing ingestion information resulted because information was not routinely collected at the start of the survey at one hospital. Many of the other patients without an ingestion amount were too ill to supply this information. Standard formulation patients with ingestion information tended to have ingested more than INTEON patients, and 29% had ingested more than 100 ml compared with 17% of INTEON patients. However, this difference in ingestion amounts would only explain a small part of the observed improvement in survival since standardising the survival rate of the standard formulation cases with ingestion information to the ingestion amount distribution of the INTEON patients only increased the estimated survival probability of standard formulation cases from 27.1% to 27.7%. Furthermore, standard formulation cases without ingestion information appeared to have ingested less than INTEON patients without ingestion information based on their higher survival rate, and the ingestion distributions of the full groups were probably closer than those of the subgroups with ingestion information.

Since the INTEON formulation was introduced in the whole country at the same time we had to rely on a before-and-after design for the survey. It is therefore possible that changes in treatment, hospital admissions, or referrals may have occurred over the period of the survey. There were some differences between the two groups in terms of treatment, with fewer INTEON patients receiving gastric lavage and prednisolone, but none of the differences were major confounders of the observed beneficial effect of INTEON on survival. [Table 6](#pmed-0050049-t006){ref-type="table"} shows that the hazard ratios with and without covariate adjustment are very similar, suggesting that the differences in treatment explain very little of the group difference in survival. There is a difference in crude survival rate between those who had lavage and those who did not, but the effect disappears when adjustment is made for ingestion amount. The lower rate of lavage in the INTEON group is more likely a consequence of factors such as the higher rate of early emesis and not an explanation for improved survival. There were a number of patients who stated that they had ingested very small amounts of either formulation but had a rapid onset of emesis. It is suspected that some of these patients ingested much more than stated and hence that rapid onset of emesis in the lower exposure groups may be an indicator of misreported exposure.

The monthly admissions over the study period suggest an overall decrease of the number of cases over time. In the survey of peripheral hospitals and care units there was no indication of a change in their referral practices over time. Changes in case ascertainment and management are therefore unlikely to have substantially contributed to the improved survival noted with INTEON. However, many hospitals indicated that the number of paraquat cases had decreased. This change may relate to shifts in the general pattern of self-harm incidents, but it is also possible that fewer patients ingesting the INTEON formulation were seeking health care.

For those patients who did not survive, there was an increase in time to death for INTEON compared to the standard formulation. This difference may become important when trying to achieve improvements in the treatment of paraquat poisoning, as it may allow more time for new or existing therapies to become effective. Our data show that in Sri Lanka self-harm patients reach hospital reasonably quickly (nearly 60% are treated within 4 h), so improved treatment of poisoning cases in addition to the INTEON formulation could have a further positive effect on survival.

While our finding of improved survival of patients in the INTEON group is encouraging the data also show that the beneficial effect of the formulation is limited by the amount of product ingested, since this was the single most important predictor of survival in both groups. It is therefore apparent that formulation changes in themselves will not be sufficient to comprehensively address the problem of mortality from self-harm with paraquat. An integrated approach has recently been proposed including generic measures to reduce self-harm incidents, as well as focusing on reducing access, reducing formulation toxicity (e.g., by reducing formulation strength), and improving the treatment of poisoning \[[@pmed-0050049-b026]\]. However, there are clear tensions between what is desirable from public health, agricultural, and industry perspectives, and this lies at the heart of the controversy over the benefits and risks of paraquat use, in particular in developing countries. A detailed discussion of this subject is beyond the scope of this paper, but can be found elsewhere \[[@pmed-0050049-b027]--[@pmed-0050049-b029]\]. Nevertheless, it is evident that, as long as paraquat and other potentially harmful pesticides continue to be widely used, a comprehensive programme to prevention and management of poisoning is needed. This is why the World Health Organization (WHO) has announced a public health initiative with the overall goal to reduce morbidity and mortality from pesticide poisoning, including improved regulatory policies, epidemiological surveillance, improved medical management and mental health-care, training in the safe handling of pesticides, and community programmes that minimise the risk of intentional and unintentional poisonings \[[@pmed-0050049-b001]\].

In conclusion, this survey shows that the introduction of a new paraquat formulation with INTEON technology has led to a significant improvement in survival of patients with paraquat poisoning. Our statistical analyses indicate that this effect is due to a real difference between the two formulations. Patients who ingested a lethal amount of the formulation survived longer with INTEON, raising the prospect of more opportunities for treatment. These encouraging results were achieved despite suboptimal homogeneity of the formulation, and future improvements in formulation technology may reduce overall toxicity even further.
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